DU-176b
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Arthroplasty, Replacement, Hip
Conditions
Arthroplasty, Replacement, Hip, Thrombosis
Trial Timeline
Jan 1, 2005 → Dec 1, 2005
NCT ID
NCT00107900About DU-176b
DU-176b is a phase 2 stage product being developed by Daiichi Sankyo for Arthroplasty, Replacement, Hip. The current trial status is completed. This product is registered under clinical trial identifier NCT00107900. Target conditions include Arthroplasty, Replacement, Hip, Thrombosis.
What happened to similar drugs?
1 of 3 similar drugs in Arthroplasty, Replacement, Hip were approved
Approved (1) Terminated (2) Active (1)
❌Tapentadol IR (CG5503) + Placebo + Oxycodone HCL IR + Tapentadol IR (CG5503)Johnson & JohnsonPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00107900 | Phase 2 | Completed |
Competing Products
9 competing products in Arthroplasty, Replacement, Hip
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM150 + Warfarin | Astellas Pharma | Phase 2 | 35 |
| Tapentadol IR (CG5503) + Placebo + Oxycodone HCL IR + Tapentadol IR (CG5503) | Johnson & Johnson | Phase 3 | 32 |
| Zoledronic acid 5mg | Novartis | Approved | 35 |
| Denosumab | Amgen | Phase 2 | 35 |
| JNJ-70033093 25 mg + JNJ-70033093 50 mg + JNJ-70033093 100 mg + JNJ-70033093 200 mg + Placebo + Enoxaparin 40 mg | Bristol Myers Squibb | Phase 2 | 35 |
| Enoxaparin sodium | Sanofi | Phase 3 | 40 |
| 48-hour ropivacaine infusions + Single dose ropivacaine + Patient controlled analgesics | Sanofi | Pre-clinical | 26 |
| Enoxaparin + Apixaban + BAY1213790 | Bayer | Phase 2 | 32 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 23 |